These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 12355959)

  • 61. A new extra long acting depot preparation of the LHRH analogue Zoladex. First endocrinological and pharmacokinetic data in patients with advanced prostate cancer.
    Dijkman GA; del Moral PF; Plasman JW; Kums JJ; Delaere KP; Debruyne FM; Hutchinson FJ; Furr BJ
    J Steroid Biochem Mol Biol; 1990 Dec; 37(6):933-6. PubMed ID: 2149507
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Comparison of efficacy and safety of 1- and 3-month luteinizing hormone-releasing hormone agonist depots as initial therapies for prostate cancer.
    Ishizuka O; Nishizawa O; Nishizawa S; Satoh T; Wajiki M; Kiyokawa H; Inoue Y; Kobayashi S; Mizusawa H; Nakagawa T
    Int J Clin Oncol; 2013 Jun; 18(3):524-30. PubMed ID: 22552359
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Leuprorelin, triptorelin: new indications. Locally advanced prostate cancer: minimally assessed me-toos.
    Prescrire Int; 2007 Dec; 16(92):243. PubMed ID: 18092407
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Randomised crossover trial to assess the tolerability of LHRH analogue administration.
    Williams G; Lindsay S; Bowsher WG
    Prostate Cancer Prostatic Dis; 2003; 6(2):187-9. PubMed ID: 12806381
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Endocrine effects, efficacy and tolerability of a 10.8-mg depot formulation of goserelin acetate administered every 13 weeks to patients with advanced prostate cancer.
    Sarosdy MF; Schellhammer PF; Soloway MS; Vogelzang NJ; Crawford ED; Presti J; Chodak GW; Mitchell P; Porter L
    BJU Int; 1999 May; 83(7):801-6. PubMed ID: 10368200
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Bicalutamide vs cyproterone acetate in preventing flare with LHRH analogue therapy for prostate cancer--a pilot study.
    Sugiono M; Winkler MH; Okeke AA; Benney M; Gillatt DA
    Prostate Cancer Prostatic Dis; 2005; 8(1):91-4. PubMed ID: 15711607
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Gn-RH antagonist possible response, after Gn-RH agonist failure in a man with metastatic prostate cancer.
    Rocco B; Ferrari M; Scardino E; Matei DV; Verweij F; Varela R; De Cobelli O
    Anticancer Res; 2005; 25(1B):577-8. PubMed ID: 15816630
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Time to normalization of testosterone after withdrawal of long time LH-RH agonist therapy in prostate cancer].
    Kaku H; Tsushima T; Nasu Y; Kumon H
    Nihon Rinsho; 2002 Dec; 60 Suppl 11():182-7. PubMed ID: 12599568
    [No Abstract]   [Full Text] [Related]  

  • 69. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.
    Teh BS; Ayala G; Aguilar L; Mai WY; Timme TL; Vlachaki MT; Miles B; Kadmon D; Wheeler T; Caillouet J; Davis M; Carpenter LS; Lu HH; Chiu JK; Woo SY; Thompson T; Aguilar-Cordova E; Butler EB
    Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1520-9. PubMed ID: 15050332
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Effectiveness, pharmacokinetics, and safety of a new sustained-release leuprolide acetate 3.75-mg depot formulation for testosterone suppression in patients with prostate cancer: a Phase III, open-label, international multicenter study.
    Marberger M; Kaisary AV; Shore ND; Karlin GS; Savulsky C; Mis R; Leuratti C; Germa JR
    Clin Ther; 2010 Apr; 32(4):744-57. PubMed ID: 20435244
    [TBL] [Abstract][Full Text] [Related]  

  • 71. A new long acting formulation of the luteinizing hormone-releasing hormone analogue goserelin: results of studies in prostate cancer.
    Debruyne FM; Dijkman GA; Lee DC; Witjes WP; del Moral F; Karthaus HF; van der Mejden AP; Plasman JW; Pull HC; Kums JJ; Idema JG; Hoefakker JW; Heijbroek RP; Kil PJ; Khoe GS
    J Urol; 1996 Apr; 155(4):1352-4. PubMed ID: 8632572
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Leuprorelin acetate in prostate cancer: a European update.
    Persad R
    Int J Clin Pract; 2002 Jun; 56(5):389-96. PubMed ID: 12137449
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers.
    Letsch M; Schally AV; Szepeshazi K; Halmos G; Nagy A
    Clin Cancer Res; 2003 Oct; 9(12):4505-13. PubMed ID: 14555524
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Monthly versus 3-monthly goserelin acetate treatment in pre-menopausal patients with estrogen receptor-positive early breast cancer.
    Masuda N; Iwata H; Rai Y; Anan K; Takeuchi T; Kohno N; Takei H; Yanagita Y; Noguchi S
    Breast Cancer Res Treat; 2011 Apr; 126(2):443-51. PubMed ID: 21221770
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Luteinizing hormone-releasing hormone analogue-induced cataract in a patient with prostate cancer.
    Al-Enezi A; Kehinde EO; Behbehani AM; Sheikh ZA
    Med Princ Pract; 2007; 16(2):161-3. PubMed ID: 17303956
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Penile length changes in men treated with androgen suppression plus radiation therapy for local or locally advanced prostate cancer.
    Haliloglu A; Baltaci S; Yaman O
    J Urol; 2007 Jan; 177(1):128-30. PubMed ID: 17162022
    [TBL] [Abstract][Full Text] [Related]  

  • 77. A randomised trial comparing the safety and efficacy of the Zoladex 10.8-mg depot, administered every 12 weeks, to that of the Zoladex 3.6-mg depot, administered every 4 weeks, in patients with advanced prostate cancer. The Dutch South East Cooperative Urological Group.
    Dijkman GA; Debruyne FM; Fernandez del Moral P; Plasman JW; Hoefakker JW; Idema JG; Sykes M
    Eur Urol; 1995; 27(1):43-6. PubMed ID: 7744141
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Leuprorelin acetate granulomas: case reports and review of the literature.
    Yasukawa K; Sawamura D; Sugawara H; Kato N
    Br J Dermatol; 2005 May; 152(5):1045-7. PubMed ID: 15888168
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Efficacy and safety of histrelin subdermal implant in patients with advanced prostate cancer.
    Schlegel PN;
    J Urol; 2006 Apr; 175(4):1353-8. PubMed ID: 16515997
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Why phase III trials of maximal androgen blockade versus castration in M1 prostate cancer rarely show statistically significant differences.
    Collette L; Studer UE; Schröder FH; Denis LJ; Sylvester RJ
    Prostate; 2001 Jun; 48(1):29-39. PubMed ID: 11391684
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.